Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the mode of action, efficacy, and safety of Janus kinase inhibitors in autoimmune dermatological conditions but reports no new clinical results.

This article discusses diffuse alopecia areata, highlighting its autoimmune characteristics, more intense inflammation, and challenges in diagnosis, but presents no new clinical findings.

This article proposes that alopecia areata may be caused by immune attacks on hair follicles after an immune privilege collapse, suggesting new therapeutic approaches targeting this immune response pattern.

This review discusses the discovery and potential therapeutic uses of proteasome inhibitors across various diseases, including cancer and autoimmune conditions, but does not present new clinical data.

This research highlights that JAK inhibitors, such as baricitinib, may effectively reverse symptoms of alopecia areata by targeting specific immune pathways, though safety and efficacy require further investigation.

In this study, researchers found that inducing mitophagy can alleviate NLRP3 inflammasome activation in outer root sheath cells under conditions of mitochondrial stress, suggesting that targeting mitophagy and inflammasome interactions may offer new therapeutic approaches for alopecia areata.

This study developed a new triamcinolone acetonide serum combined with a microneedling device, showing promise for treating alopecia areata by targeting hair follicles in a less invasive, patient-friendly way with confirmed drug solubility, compatibility, and safety.

This study suggests that CD8+ cytotoxic T lymphocytes play a crucial role in the development of alopecia areata, based on observations in rodent models that mimic human autoimmune disease.

This study systematically reviews the Wnt/β-catenin signaling pathway, discussing its origin, composition, function, involvement in tumors and diseases, and the development of small-molecular compounds targeting this pathway for disease treatment.

This review identifies shared interferon gamma-driven immune pathways in vitiligo and alopecia areata, revealing potential targets for new treatments, but reports no clinical results.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review explores the complex factors involved in alopecia areata, such as immune and genetic influences, and discusses advances in diagnostic and therapeutic approaches, while reporting no new clinical results.

In this study, a patient with clinically amyopathic dermatomyositis experienced persistent skin issues despite treatment, highlighting questions about type I interferon's role in skin disorders and potential IFN-targeted therapies for cutaneous lupus erythematosus and dermatomyositis.

This case report describes a man's permanent skin and hair whitening, and generalized anhidrosis following allogeneic stem cell transplant, linked to immune-mediated destruction of melanocytes.

In this review, researchers explore evidence showing that JAK inhibitors, particularly baricitinib and deuruxolitinib, are effective in promoting hair regrowth in severe alopecia areata while maintaining acceptable safety profiles, though long-term data remains scarce.

This study found that anti-CD44 treatment inhibited leukocyte migration in alopecia areata and eczema, suggesting targeted therapies could enhance contact sensitizer treatment for alopecia areata.

This study suggests that NKG2D+ Vδ1 T cells may contribute to hair follicle pathology in alopecia areata by recognizing stressed keratinocytes and inducing immune privilege collapse.

This study reports that CD200R expression is significantly reduced in a mouse model of scarring alopecia, suggesting a potential role for this pathway in immune regulation and hair follicle protection.

This article reviews alopecia areata treatment strategies, noting that while various therapies exist, none are curative or preventive and many lack randomized, controlled trials.

This study reports a strong association between the MICA locus, specifically the MICA∗3-DR∗6-DQ6 haplotype, and Alopecia Areata in families.

In this study, increased production of CXCL10 was associated with the infiltration of Th1 and Tc1 cells in acute alopecia areata, suggesting a possible new target for treatment.

This review discusses the pathomechanism and pathology of alopecia areata, its classifications, and associated diseases, but reports no new clinical results, highlighting the importance for current and future treatment considerations.

In this study on C3H/HeJ-engrafted mice, a single injection of BMD-1141 significantly increased anagen hair follicle counts and enhanced hair regrowth compared to daily high-dose ruxolitinib, suggesting it stimulates hair growth by influencing the hair cycle rather than altering immune response.

Smart microneedles using advanced tech could improve psoriasis treatment.

The authors discussed that SOCS1 and SOCS3's inhibition of JAKs plays a significant role in the development of JAK inhibitor drugs for skin inflammatory diseases and malignancies.

This review discusses the potential link between gut microbiota alterations and the onset and progression of alopecia areata, identifying it as a possible pathogenetic factor and therapeutic target, but reports no new clinical results.

In this review, the potential role of the hormone prolactin in skin biology and its implications for treating skin diseases and hair disorders are explored, with a focus on its stress-related impacts and possible immunomodulatory function in the context of COVID-19.

This review highlights the complex role of leukocyte migration in both driving inflammation and facilitating its resolution, suggesting that targeted modulation of this process could improve therapeutic strategies for inflammatory diseases.

This study reported improvement in hair loss lesions in C3H/HeJ mice with alopecia areata following treatment with the CCR5 inhibitor maraviroc, alongside reduced infiltration of specific T cells in the lesions.

This study found that cyclosporine treatment led to clinical improvements in dogs with sebaceous adenitis, with noticeable benefits within four months and more substantial outcomes after 12 months of continuous therapy.